Long term safety of IVIg therapy in multiple sclerosis: 10 years experience

References

• Lassmann H. Multiple sclerosis pathology: Evolution of pathogenetic concepts. Brain Pathol 2005; 15: 217–222
   PubMed Web of Science ®Google Scholar
• Achiron A, Kishner I, Sarova-Pinhas I, Raz H, Faibel M, Stern Y, Lavie M, Gurevich M, Dolev M, Magalashvili D, Barak Y. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: A randomized, double-blind, placebo-controlled trial. Arch Neurol 2004; 61: 1515–1520
   PubMed Web of Science ®Google Scholar
• Hauser SL, Goodin DS. Multiple sclerosis and other demyelinating diseases. Harrison's principles of internal medicine16th ed., DL Kasper, E Braunwald, AS Fauci, SL Hauser, DL Longo, JL Jameson. McGraw-Hill, New York 2005; 2461–2471
   Google Scholar
• McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–127
   PubMed Web of Science ®Google Scholar
• Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in multiple sclerosis group. N Engl J Med 1998; 339: 285–291
   PubMed Web of Science ®Google Scholar
• Rizvi SA, Agius MA. Current approved options for treating patients with multiple sclerosis. Neurology 2004; 63: S8–14
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing–remitting multiple sclerosis: A meta-analysis. Eur J Neurol 2002; 9: 557–563
   PubMed Web of Science ®Google Scholar
• Raouva L, Rovensky J, Shoenfeld Y. High dose intravenous immunoglobulins: A new step in the treatment of systemic lupus erythematosus. IMAJ 2000; 388–392
   Google Scholar
• Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: An update for clinicians. Transfusion 2003; 43: 1460–1480
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Katz U. IVIg therapy in autoimmunity and related disorders: Our experience with a large cohort of patients. Autoimmunity 2005; 38: 123–137
   PubMed Web of Science ®Google Scholar
• Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, Gornish M, Elizur A, Goldhammer Y, Sarova-Pinhas I. Intravenous immunoglobulin treatment in multiple sclerosis, effect on relapses. Neurology 1998; 50: 398–402
   PubMed Web of Science ®Google Scholar
• Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing–remitting multiple sclerosis. Austrian Immunoglobulin in multiple sclerosis study group. Lancet 1997; 349: 589–593
   PubMed Web of Science ®Google Scholar
• Lewanska M, Siger-Zajdel M, Selmaj K. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: Clinical and MRI assessment. Eur J Neurol 2002; 9: 565–572
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M, Kirsmeier H, Larsen VA, Lee ML. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50: 1273–1281
   PubMed Web of Science ®Google Scholar
• Achiron A, Kishner I, Dolev M, Stern Y, Dulitzky M, Schiff E, Achiron R. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol 2004; 251: 1133–1137
   PubMed Web of Science ®Google Scholar
• Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: Adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29: 173–184
   PubMed Web of Science ®Google Scholar
• Sherer Y, Levy Y, Langevitz P, Rauova L, Fabrizzi F, Shoenfeld Y. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology 2001; 62: 133–137
   PubMed Web of Science ®Google Scholar
• Brannagan TH, 3rd, Nagle KJ, Lange DJ, Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996; 47: 674–677
   PubMed Web of Science ®Google Scholar
• Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: Incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica 1993; 78: 35–40
   PubMedGoogle Scholar
• Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney – a two-edged sword. Semin Arthritis Rheum 2004; 34: 593–601
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Clark WM. Strokes, thromboembolic events, and IVIg: Rare incidents blemish an excellent safety record. Neurology 2003; 60: 1736–1737
   PubMedGoogle Scholar
• Haplea SS, Farrar JT, Gibson GA, Laskin M, Pizzi LT, Asbury AK. Thromboembolic events associated with intravenous immunoglobulin therapy. Neurology 1997; 48: A54
   Google Scholar
• Stangel M, Hartung HP, Marx P, Gold R. Side effects of high-dose intravenous immunoglobulins. Clin Neuropharmacol 1997; 20: 385–393
   Google Scholar
• Katz U, Shoenfeld Y. Review: Intravenous immunoglobulin therapy and thromboembolic complications. Lupus 2005; 14: 802–808
   PubMed Web of Science ®Google Scholar